Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
- Jan Taprogge , Iain Murray , Hannah Sharman , Paul Gape , Francesca Leek , Carla Abreu , Lenka Vávrová , Kate Newbold , Kee H Wong , Markus Luster , Frederik A Verburg , Tino Schurrat , Lavinia Vija , Frédéric Courbon , Delphine Vallot , Manuel Bardiès , Sarah Schumann , Uta Eberlein , Michael Lassmann , Glenn Flux
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Post-operative stimulated thyroglobulin levels are effective predictors of differentiated thyroid cancer treatment success. A stimulated thyroglobulin level below 1 ng/mL suggests radioiodine therapy may not be beneficial.
Area Of Science
- Endocrinology
- Nuclear Medicine
- Oncology
Background
- Serum thyroglobulin (Tg) monitoring is crucial for differentiated thyroid cancer (DTC) management post-thyroidectomy and radioiodine therapy.
- Predictive biomarkers can identify patients at risk of recurrence or treatment failure.
Purpose Of The Study
- To compare the predictive value of post-operative stimulated thyroglobulin (sTg) levels and absorbed dose to the thyroid remnant for radioiodine therapy success in DTC.
- To identify patients who may not benefit from radioiodine therapy.
Main Methods
- Observational clinical studies (MEDIRAD) in France, Germany, and the UK.
- Recruitment of DTC patients treated with 1.1 or 3.7 GBq radioiodine under recombinant human thyrotropin (rhTSH) stimulation or thyroid hormone withdrawal.
- Determination of maximum absorbed dose to the thyroid remnant and comparison with post-operative sTg for predicting ablation success.
Main Results
- Ninety-four patients with negative antithyroglobulin antibodies were analyzed.
- Post-operative sTg levels demonstrated strong predictive power for ablation success (ROC AUC 0.83 ± 0.05).
- A dose-response relationship was observed between absorbed dose and ablation success in patients with sTg ≥1 ng/mL.
Conclusions
- Post-operative sTg and absorbed dose can guide personalized management of DTC.
- Patients with post-operative sTg <1 ng/mL are unlikely to benefit from radioiodine therapy.
- These biomarkers help identify patients requiring further treatment or intensified follow-up.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

